PCPhilippe Carron

Philippe Carron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Carron has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The development and validation of a new diagnostic sonographic enthesitis score for psoriatic arthritis: Diagnostic Ultrasound Enthesitis Tool ( DUET )

    by Lihi Eder, Andre L. Ribeiro, Ricardo Acayaba de Toledo, Catherine Bakewell, Philippe Carron, Basant Elnady, Amir Haddad, Arthur Kavanaugh, Arnon Katz, Minna J. Kohler, et al.

    Objective: The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a new sonographic scoring system for enthesitis to aid PsA diagnosis. Methods: We prospectively enrolled patients with early PsA, psoriasis without arthritis (PsO), and non‐inflammatory musculoskeletal symptoms as controls (CTL) from 17 centers. A standardized ultrasound assessment of 16 entheseal sites was performed and images were centrally scored by three blinded readers for inflammatory and structural entheseal lesions. Using a stepwise approach with logistic regression models stratified by age, we identified optimal lesion combinations, weightings, and entheseal sites for distinguishing PsA from CTL. Age‐specific cut‐off points were selected to maintain specificity above 70%. Performance was assessed in a validation cohort of PsA and CTL. Results: We included 213 PsA, 100 PsO, and 106 CTL in the discovery cohort. The final DUET score combined weighted inflammatory (hypoechogenicity + thickening + Doppler grade x 2) and structural (enthesophyte grade + erosion x 3) scores at three entheseal sites: Achilles, proximal patellar tendon insertion, and triceps. Age stratification (≤55 vs. >55 years) improved discriminative performance. In the discovery cohort, DUET achieved an AUC of 0.65, with specificity of 73‐74% and sensitivity of 47‐49%. In an external validation cohort (101 PsA, 69 CTL), specificity improved to 74‐100% with similar sensitivity (49‐52%). Sensitivity increased up to 63% in patients with tender entheses. Conclusion: DUET is a novel, externally validated sonographic enthesitis score that could support the diagnostic assessment of patients with early PsA, particularly in individuals with tender entheses.

  • Open Access

    The ASAS core set for the assessment of axial spondyloarthritis in clinical practice

    by Astrid van Tubergen, Marius L Smits, Xenofon Baraliakos, Anna Moltó, Elena Nikiphorou, Wilson Bautista-Molano, Philippe Carron, Adrian Ciurea, Jo Davies, Warren Fong, et al.

  • Open Access

    Selection of relevant domains and instruments for the ASAS core set to assess axial spondyloarthritis in clinical practice: a Delphi survey of stakeholders

    by Marius L. Smits, Victoria Navarro-Compán, Xenofon Baraliakos, Anna Moltó, Elena Nikiphorou, Wilson Bautista-Molano, Philippe Carron, Adrian Ciurea, Jo Davies, Warren Fong, et al.


  • Drug‐Free Remission in Early Peripheral Spondyloarthritis, Including Psoriatic Arthritis: 10‐Year Follow‐Up From the CRESPA Trial

    by Caroline Damen, Ann‐Sophie De Craemer, Casper Webers, Dirk Elewaut, Gaelle Varkas, Filip Van Den Bosch, Philippe Carron

    Objective: The aim of this study was to provide a descriptive analysis of the 10‐year follow‐up data from the Clinical Remission in Peripheral Spondyloarthritis (CRESPA) study. Here, patients fulfilling the Assessment of Spondyloarthritis International Society peripheral spondyloarthritis (pSpA) classification criteria, with symptom duration ≤12 weeks, were randomized to golimumab 50 mg every four weeks or placebo. Our aims were to assess the proportion of patients in (drug‐free) clinical remission and identify baseline predictors of achieving (drug‐free) remission at 10‐year follow‐up. Methods: All patients from the original CRESPA study were invited for a standardized evaluation 10 years after inclusion. Clinical remission was defined as the absence of swollen joints, enthesitis, or dactylitis. Results: Of 60 original patients, 49 were evaluated after a mean (±SD) of 10.5 (±0.87) years. Of the patients, 81.6% (40 of 49) were in clinical remission, of whom 30.6% (15 of 49) achieved longstanding drug‐free remission. Remission was not linked to baseline characteristics like sex, age, HLA‐B27 positivity, psoriasis, or initial treatment allocation. Patients without psoriasis at baseline were significantly more likely to achieve drug‐free remission (odds ratio 9.1, 95% confidence interval 1.8–50), with 48.1% patients with nonpsoriatic pSpA (13 of 27) remaining in drug‐free remission. Health‐related quality of life and physical function were significantly better in patients in remission. Conclusion: Remission induction with golimumab in patients with early pSpA enables achievement of sustained clinical remission in the majority of patients, with one‐third of patients attaining drug‐free remission. Strikingly, almost half of patients with nonpsoriatic pSpA remained in drug‐free remission. These findings strongly suggest that early, intensive treatment has the potential to achieve long‐term disease control, potentially leading to sustained drug‐free remission in a subset of patients.

  • Open Access

    Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project

    by Sofia Ramiro, Dafne Capelusnik, Clementina López-Medina, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Wilson Bautista-Molano, Annelies Boonen, Filip Van Den Bosch, Philippe Carron, et al.

  • Diagnostic Value and Treatment Responsiveness of Ultrasonography Features in Correlation With Clinical Findings in Early Peripheral Spondyloarthritis

    by Wannes Van Hooste, Josephine Braekman, Thomas Renson, Roos Colman, Filip Van Den Bosch, Dirk Elewaut, Philippe Carron

    Objective: To investigate the diagnostic performance of ultrasonography features in the evaluation of enthesitis and arthritis in very early peripheral spondyloarthritis (pSpA). Methods: The Clinical Remission in Peripheral Spondyloarthritis (CRESPA) trial was a double‐blinded, placebo‐controlled trial investigating induction of clinical remission in very early pSpA (symptom duration < 12 weeks) using tumor necrosis factor α (TNFα)–inhibition. Standardized clinical and ultrasonography evaluation of four pairs of entheses and eight pairs of lower limb joints were performed repeatedly in 54 patients. Analyses focused on the prevalence of ultrasonography features of joints and entheses, their correlation with clinical findings, and their response to treatment. Results: At baseline, synovial hypertrophy was uncommon in this early pSpA cohort and showed no independent predictive value for clinical evaluation. In contrast, Power Doppler (PD) ≥1 (odds ratio [OR] 9.5) and ultrasonography joint effusion (OR 8.3) were strong predictors of a swollen joint. Golimumab treatment significantly predicted resolution of PD signal, synovial hypertrophy, and joint effusion on ultrasonography evaluation compared to placebo. Among entheses, 45% (21 of 46) of clinical tender sites displayed no ultrasonography abnormality, whereas 19% (72 of 386) of nontender entheses did. Across all 432 entheses at baseline, only entheseal thickening (OR 10.89) and PD ≥1 (OR 5.94) predicted tenderness. Treatment with golimumab was also associated with disappearance of entheseal thickening, hypoechogenicity, and PD signal. Conclusion: Ultrasonography in enthesitis and arthritis demonstrates high responsiveness to TNFα inhibition in early pSpA but is limited by nonspecific findings and clinical overestimation of enthesitis. Development of standardized scoring systems and validated thresholds is essential to improve diagnostic accuracy and treatment monitoring.

  • Work participation and work disability in Belgian patients with systemic sclerosis

    by Ine Desimpele, Ann-Sophie De Craemer, Saskia Decuman, Annick Viaene, Piet Mortelé, Lauren Delmez, Philippe Carron, Dirk Elewaut, Filip Van Den Bosch, Vanessa Smith

    Objectives: (1) Update data on work participation among patients with SSc followed in a multidisciplinary setting at a Belgian reference centre; (2) Investigate associations between work outcomes, personal, disease-related and contextual factors. Methods: One hundred and eight adult SSc patients, 84% fulfilling the 2013 ACR/EULAR criteria for SSc, were questioned on their socio-economic status during outpatient visits at Ghent University Hospital (February 2020–March 2021). Employment rate was compared with the general population after adjustment for age and sex. Associations between two work-related outcomes and socio-demographic and clinical variables were explored through binary logistic regression (outcome 1: having a paid job) and negative binomial regression (outcome 2: sick leave). Results: Among 81/108 (75%) participants of working age (18–65 y/o), crude employment rate was 64%, corresponding to a standardized employment ratio of 0.90 (95% CI 0.69–1.17). Work disability was the most common reason for not having a paid job (20%), with patients being older, less well educated and more functionally impaired compared with those with a paid job. Health-related sick leave in the previous year was substantial (79%); the number of days absent from work was significantly associated with internal organ involvement (incidence rate ratio, IRR, 0.3 [95% CI 0.1–0.8]) and working full-time (IRR 0.3 [95% CI 0.1–0.7]). Conclusion: Work participation in SSc patients is comparable to the general population, although work disability and sick leave remain substantial. Socio-demographic and job-related factors should be taken into account when assessing work outcomes in SSc, rather than basing work outcomes on disease characteristics alone.

  • Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study

    by Zuzanna Łukasik, Ann‐Sophie De Craemer, Thomas Renson, Liselotte Deroo, Gaëlle Varkas, Manouk de Hooge, Jan Lenaerts, Anne Hoorens, Claude Cuvelier, Triana Lobatón Ortega, et al.

    Objective: To evaluate the efficacy of tight‐control, rapid escalation to tumor necrosis factor inhibition in early axial spondyloarthritis (axSpA) in relation to gut inflammation. Methods: GO‐GUT (NCT03270501) was a prospective, open‐label, 52‐week trial in treatment‐naïve patients with axSpA with less than one year of symptom duration and high disease activity. At baseline, patients underwent ileocolonoscopy with histopathological evaluation of the gut mucosa. Next, all patients received two different nonsteroidal anti‐inflammatory drugs in optimal dose for a period of four weeks. If inactive disease, defined as Ankylosing Spondylitis Disease Activity Score (ASDAS) with CRP <1.3, or clinically important improvement (ΔASDAS‐CRP ≥ 1.1) resulting in low disease activity (ASDAS‐CRP <2.1) was not achieved, monotherapy with 50 mg golimumab every four weeks was initiated. Patients were observed until they achieved sustained clinical remission (ASDAS‐CRP <1.3 at two consecutive visits with 12 weeks interval) or end of trial. Upon achievement of sustained clinical remission, all medication was discontinued, and the possibility of drug‐free remission was evaluated. Results: Fifty‐eight patients were included in the trial. Microscopic gut inflammation was present in 28.6% of patients, which was predominantly acute inflammation. An escalation of therapy to golimumab was required for 72.7% of patients. The primary study endpoint of sustained clinical remission was reached by 61.8% of patients, irrespective of gut inflammation. Treatment discontinuation resulted in disease relapse within one year in 78.1% of patients. Conclusion: Applying a treat‐to‐target approach in treatment‐naïve early axSpA allows to induce high rates of sustained clinical remission, regardless of the presence of microscopic gut inflammation.


  • Open Access

    Patient-tailored training programme on cardiorespiratory fitness, trunk strength and mobility leads to significantly better outcomes in individuals with axial spondyloarthritis

    by Sophie De Mits, Tine Willems, Patrick Calders, Lieven Danneels, Gaëlle Varkas, Filip Van Den Bosch, Dirk Elewaut, Philippe Carron

    Background: Axial spondyloarthritis (axSpA) impairs trunk strength, mobility and cardiorespiratory fitness. Despite exercise being a key treatment, few studies have examined a combined trunk mobility, strength and cardiorespiratory training programme. This prospective interventional study assessed the benefits of a personalised training programme based on baseline physical tests. Methods: People with axSpA underwent cardiopulmonary exercise testing (CPET) and trunk strength/mobility assessments using the David Back Concept (DBC) devices. Strength and mobility deficits were calculated, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI) and chest expansion (CE) were recorded pre-intervention and post-intervention. The 8-week programme included two sessions per week of cardiorespiratory training (based on ventilatory threshold, heart rate monitored via a Polar device), followed by resistance/mobility exercises on DBC devices. Training intensity was tailored to each individual’s one-repetition-maximum and range of motion at baseline. Post-intervention, CPET and DBC tests were repeated. Changes were analysed using linear mixed models. Results: 30 individuals with axSpA (14 males/16 females, age 42±11.2 years, BASDAI 3.5±2.1, BASFI 2.8±2.2, BASMI 2.0±1.1, CE 4.5±2.0 cm) participated; two were lost to follow-up. Strength increased by 14.1% (p<0.001) and mobility by 14.9% (p<0.001). Significant improvements occurred in oxygen pulse (p=0.004), ventilatory efficiency (p<0.001), anaerobic threshold (p=0.002) and mechanical efficiency (p=0.021). BASDAI (2.9±2.2, p=0.021) and CE (5.0±2.1, p=0.020) improved significantly; BASMI (1.8±1.0, p=0.053) showed borderline improvement, while BASFI remained unchanged (2.4±2.1, p=0.092). Conclusion: A combined, tailored and baseline-guided training programme significantly enhanced cardiorespiratory fitness, trunk strength and trunk mobility in individuals with axSpA, supporting individualised exercise interventions to improve outcomes and reduce functional limitations.


  • Open Access

    Measurement properties of disease activity instruments in peripheral spondyloarthritis: a post-hoc analysis of the CRESPA trial

    by Clementina López-Medina, Dafne Capelusnik, Casper Webers, Filip Van Den Bosch, Annelies Boonen, Philippe Carron, Anna Molto, Sofia Ramiro

    Background: Unravelling the performance of disease activity measures in peripheral spondyloarthritis (pSpA) is crucial for the development of clinical studies. We aimed to evaluate the construct validity and discriminatory capacity of various instruments assessing disease activity and response criteria in patients with pSpA. Methods: Post-hoc analysis of the CRESPA randomised controlled trial including patients with early active pSpA. Patients were randomised to golimumab (GOL) or placebo (PBO). Data of the placebo-controlled part until week 12 were used. Construct validity (known group discrimination assessed with standardised mean difference, SMD) in the 12-week data, longitudinal construct validity (ie, standardised response mean and effect size) and trial discrimination (SMD) of several disease activity instruments were assessed. As part of trial discrimination, a χ2 test was performed for binary outcomes. Results: A total of 60 patients (40 GOL, 20 PBO) were included. Construct validity was better for composite outcomes (ie, Disease Activity in Psoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS)—higher SMD between active and inactive patients). Longitudinal construct validity was consistently good for composite outcomes (eg, ASDAS, DAPSA) and global assessments (Patient Global Assessment (PGA), Physician Global Assessment (PhGA)). Clinical trial discrimination was good for composites (BASDAI, ASDAS, DAPSA), global assessments (PGA, PhGA) and joint counts (swollen joint count (SJC66) and tender joint count (TJC68)). Among binary outcomes, trial discrimination was strongest for clinical remission (ie, absence of arthritis, enthesitis and dactylitis), BASDAI50, DAPSA-Low Disease Activity (LDA) and ASDAS-LDA. Conclusion: While both composite and global outcome measurement instruments performed well in pSpA, composite scores like DAPSA, ASDAS and BASDAI showed better construct validity. The clinical remission definition was the most discriminatory response criterion.